halofuginone has been researched along with Uterine Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hodges, SJ; Jennell, JL; Washburn, S | 1 |
| Genina, O; Lavelin, I; Nagler, A; Ohana, M; Pines, M | 1 |
2 other study(ies) available for halofuginone and Uterine Diseases
| Article | Year |
|---|---|
Halofuginone- and chitosan-coated amnion membranes demonstrate improved abdominal adhesion prevention.
Topics: Abdomen; Amnion; Angiogenesis Inhibitors; Animals; Cellulose, Oxidized; Chitosan; Female; Ischemia; Laparotomy; Piperidines; Postoperative Complications; Quinazolinones; Random Allocation; Rats; Rats, Sprague-Dawley; Tissue Adhesions; Treatment Outcome; Uterine Diseases; Uterus | 2010 |
Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
Topics: Administration, Oral; Animals; Collagen; Female; Gene Expression; In Situ Hybridization; Injections, Intraperitoneal; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Tissue Adhesions; Uterine Diseases | 1999 |